$PLRZJun 15, 2026, 12:05 PMAI processed
Polyrizon launches human study to measure NASARIX nasal residence time to support regulatory filings
AI Summary
Polyrizon signed agreements with a leading European university medical center and a CRO to run a single-site human performance/characterization study measuring nasal residence time of NASARIX (PL-14) in healthy volunteers using serial endoscopic visualization. The data are intended to quantify expected duration of the product's protective barrier and to support the company's verification & validation program and planned regulatory submissions (including FDA), though timing and enrollment details were not disclosed.
Positives
- Agreement executed with a leading European university medical center and an experienced CRO to run the study
- Study will use high-resolution, serial endoscopic measurements to quantify in vivo nasal residence/retention of NASARIX
- Results are explicitly intended to support the company's V&V program and planned regulatory strategy, including FDA submissions
Negatives
- Study is a human performance/characterization trial in healthy volunteers, not an efficacy or safety clinical trial
- Single-site study; company did not disclose enrollment size, timing, or study start date
- Authorization from European health authorities and ethics committees is still required before commencement